187 related articles for article (PubMed ID: 34597380)
21. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data.
Freedland SJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Ryan CJ
Curr Med Res Opin; 2021 Apr; 37(4):609-622. PubMed ID: 33476184
[TBL] [Abstract][Full Text] [Related]
22. Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System.
Nguyen CB; Kobe C; Kumbier KE; Bauman J; Burns JA; Tsao PA; Sparks JB; Skolarus TA; Caram MEV
JCO Oncol Pract; 2024 Jan; 20(1):59-68. PubMed ID: 38085028
[TBL] [Abstract][Full Text] [Related]
23. Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.
Yamasaki M; Yuasa T; Uehara S; Fujii Y; Yamamoto S; Masuda H; Fukui I; Yonese J
Int J Clin Oncol; 2016 Dec; 21(6):1191-1195. PubMed ID: 27402103
[TBL] [Abstract][Full Text] [Related]
24. An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.
Liede A; Wade S; Lethen J; Hernandez RK; Warner D; Abernethy AP; Finelli A
Clin Ther; 2018 Apr; 40(4):536-549.e3. PubMed ID: 29395290
[TBL] [Abstract][Full Text] [Related]
25. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
[TBL] [Abstract][Full Text] [Related]
26. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
27. Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
Mitchell AP; Persaud S; Palyca P; Salner A; Farooki A; Ostroff JS; Morris MJ; Chimonas S
Prostate; 2024 Feb; 84(2):177-184. PubMed ID: 37846041
[TBL] [Abstract][Full Text] [Related]
28. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
29. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
Smith MR; Coleman RE; Klotz L; Pittman K; Milecki P; Ng S; Chi KN; Balakumaran A; Wei R; Wang H; Braun A; Fizazi K
Ann Oncol; 2015 Feb; 26(2):368-74. PubMed ID: 25425475
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
31. Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects.
Fusco V; Di Maio M; Valsecchi AA; Santini D; Tucci M; De Giorgi U; Bossi P; Ibrahim T; Cavanna L; Lanzetta G; Rossi M; Rossetti G; Airoldi M; Comandone A; Cinieri S
Support Care Cancer; 2024 Mar; 32(3):202. PubMed ID: 38427111
[TBL] [Abstract][Full Text] [Related]
32. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
Huang FM; Li XH; Liang Y
Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
[TBL] [Abstract][Full Text] [Related]
33. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
Miller K; Steger GG; Niepel D; Lüftner D
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
[TBL] [Abstract][Full Text] [Related]
34. Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.
Cheung FY
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():13-15. PubMed ID: 30489032
[TBL] [Abstract][Full Text] [Related]
35. Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer.
Heath EI; Dyson GE; Cackowski FC; Hafron J; Powell I
Clin Genitourin Cancer; 2022 Dec; 20(6):524-532. PubMed ID: 35864053
[TBL] [Abstract][Full Text] [Related]
36. Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab.
Suarez-Almazor ME; Herrera R; Lei X; Chavez-MacGregor M; Zhao H; Giordano SH
Cancer; 2020 Sep; 126(17):3929-3938. PubMed ID: 32573777
[TBL] [Abstract][Full Text] [Related]
37. Bone metastases and bone loss medical treatment in prostate cancer patients.
Safriadi F
Acta Med Indones; 2013 Jan; 45(1):76-80. PubMed ID: 23585414
[TBL] [Abstract][Full Text] [Related]
38. Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
Zekri J; Farag K; Yousof O; Zabani Y; Mohamed W; Ahmed GA
J Oncol Pharm Pract; 2020 Jun; 26(4):906-911. PubMed ID: 31575357
[TBL] [Abstract][Full Text] [Related]
39. Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis.
Onukwugha E; Albarmawi H; Sun K; Mullins CD; Aly A; Hussain A
Urol Oncol; 2018 Jul; 36(7):340.e23-340.e31. PubMed ID: 29724482
[TBL] [Abstract][Full Text] [Related]
40. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.
Saylor PJ
Asian J Androl; 2014; 16(3):341-7. PubMed ID: 24435057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
